Holmium laser resection of the prostate is more cost effective than transurethral resection of the prostate: results of a randomized prospective study


      Objectives. A cost-effectiveness analysis was carried out comparing electrosurgical transurethral resection of the prostate (TURP) with holmium:yttrium-aluminum-garnet laser resection of the prostate (HoLRP).
      Methods. One hundred twenty patients with benign prostatic hyperplasia and urodynamically proved obstruction were randomized to undergo either TURP or HoLRP. Economic and clinical outcome data were recorded prospectively out to 1 year postoperatively.
      Results. The HoLRP group experienced fewer complications and had a shorter hospital stay and catheterization time than the TURP group, with equivalent clinical outcomes at 12 months. HoLRP cost 24.5% less (New Zealand dollars $651) than TURP during the first year.
      Conclusions. Because the clinical outcomes out to 1 year were equivalent, HoLRP was more cost-effective than TURP. On the basis of these savings, a minimum of 93 cases per year are required to recover the capital and service costs of the holmium:yttrium-aluminum-garnet laser.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Chapple C.R
        Introduction and concluding remarks.
        Eur Urol. 1999; 36: 1-6
        • Holtgrewe H.L
        • Bay-Neilsen H
        • Carlsson P
        • et al.
        The economics of the management of lower urinary tract symptoms and benign prostatic hyperplasia.
        in: Dennis L Griffiths K Khoury S Proceedings of the Fourth International Consultation on Benign Prostatic Hyperplasia (BPH). Plymbridge Distributors, Plymouth1998: 61-81
        • Holtgrewe H.L
        Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia.
        Urology. 1998; 51: 1-7
        • Lukacs B
        Management of symptomatic BPH in France.
        Eur Urol. 1999; 36: 14-20
        • Berges R.R
        • Pientka L
        Management of the BPH syndrome in Germany.
        Eur Urol. 1999; 36: 21-27
        • Tubaro A
        • Montanari E
        Management of symptomatic BPH in Italy.
        Eur Urol. 1999; 36: 28-32
        • McNicholas T.A
        Management of symptomatic BPH in the UK.
        Eur Urol. 1999; 36: 33-39
        • Kortt M.A
        • Bootman J.L
        The economics of benign prostatic hyperplasia treatment.
        Clin Ther. 1996; 18: 1227-1241
        • Gilling P.J
        • Cass C.B
        • Cresswell M.D
        • et al.
        Holmium laser resection of the prostate.
        Urology. 1996; 47: 48-51
        • Gilling P.J
        • Mackey M
        • Cresswell M
        • et al.
        Holmium laser versus transurethral resection of the prostate.
        J Urol. 1999; 162: 1640-1644
        • Chandhoke P.S
        • DeAntoni E
        Cost-effectiveness analysis.
        J Endourol. 1998; 12: 485-491
        • Fraundorfer M.R
        • Gilling P.J
        Holmium:YAG laser enucleation of the prostate combined with mechanical morcellation.
        Eur Urol. 1998; 33: 69-72
        • Gilling P.J
        • Kennett K
        • Das A.K
        • et al.
        Holmium laser enucleation of the prostate (HoLEP) combined with transurethral tissue morcellation.
        J Endourol. 1998; 12: 457-459